Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation "REMI-2"

Recruiting

Phase N/A Results N/A

Trial Description

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Because of its major impact on the general morbidity and risk of stroke, AF is a great concern for public health. Several mechanisms, including endothelial dysfunction and inflammatory processes, have been postulated as predisposing factors for AF, as well as for stroke.
Both clinical and experimental studies highlight inflammation as a predisposing factor for AF and its complications. Nevertheless, the source of high inflammatory proteins in patients with AF is still unknown. We hypothesized that multilevel intracardiac and extracardiac (left femoral vein, coronary sinus, left atrium, pulmonary vein) measurements of several inflammatory proteins (VEGF) would help assessing the extent and the source of inflammation in AF patients.
The measurement of von Willebrand factor (vWF) levels in multiple vascular sites would also help to define the site of endothelial dysfunction and of production of this thrombogenic factor.
Although AF is associated with an increased risk of stroke, the risk is not homogeneous. Permanent and persistent AF are associated with similar thromboembolic risk to that of paroxysmal AF.

Conditions

Interventions

  • Blood samples Other
    Intervention Desc: Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
    ARM 1: Kind: Experimental
    Label: atrial fibrillation
    Description: Patients with atrial fibrillation
    ARM 2: Kind: Experimental
    Label: Control
    Description: Patients without atrial fibrillation

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Basic Science
  • Intervention: Parallel Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary VEGF concentration Day one No
Primary vWF concentration Day one No

Sponsors